JP2018508572A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508572A5 JP2018508572A5 JP2017560890A JP2017560890A JP2018508572A5 JP 2018508572 A5 JP2018508572 A5 JP 2018508572A5 JP 2017560890 A JP2017560890 A JP 2017560890A JP 2017560890 A JP2017560890 A JP 2017560890A JP 2018508572 A5 JP2018508572 A5 JP 2018508572A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- immune checkpoint
- inhibitor
- cancer
- checkpoint inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022175377A JP7564172B2 (ja) | 2015-02-12 | 2022-11-01 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
| JP2024167302A JP2024174070A (ja) | 2015-02-12 | 2024-09-26 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115468P | 2015-02-12 | 2015-02-12 | |
| US62/115,468 | 2015-02-12 | ||
| US201562255259P | 2015-11-13 | 2015-11-13 | |
| US62/255,259 | 2015-11-13 | ||
| PCT/US2016/017602 WO2016130839A1 (en) | 2015-02-12 | 2016-02-11 | Use of plinabulin in combination with immune checkpoint inhibitors |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021001505A Division JP7157181B2 (ja) | 2015-02-12 | 2021-01-07 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
| JP2022175377A Division JP7564172B2 (ja) | 2015-02-12 | 2022-11-01 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508572A JP2018508572A (ja) | 2018-03-29 |
| JP2018508572A5 true JP2018508572A5 (https=) | 2019-03-22 |
| JP7243021B2 JP7243021B2 (ja) | 2023-03-22 |
Family
ID=56615698
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560890A Active JP7243021B2 (ja) | 2015-02-12 | 2016-02-11 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
| JP2021001505A Active JP7157181B2 (ja) | 2015-02-12 | 2021-01-07 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
| JP2022175377A Active JP7564172B2 (ja) | 2015-02-12 | 2022-11-01 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
| JP2024167302A Pending JP2024174070A (ja) | 2015-02-12 | 2024-09-26 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021001505A Active JP7157181B2 (ja) | 2015-02-12 | 2021-01-07 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
| JP2022175377A Active JP7564172B2 (ja) | 2015-02-12 | 2022-11-01 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
| JP2024167302A Pending JP2024174070A (ja) | 2015-02-12 | 2024-09-26 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180028531A1 (https=) |
| EP (1) | EP3256130A4 (https=) |
| JP (4) | JP7243021B2 (https=) |
| KR (2) | KR20170117113A (https=) |
| CN (2) | CN107427510A (https=) |
| AU (3) | AU2016219204B2 (https=) |
| CA (1) | CA2975729A1 (https=) |
| CL (1) | CL2017002050A1 (https=) |
| HK (1) | HK1247816A1 (https=) |
| IL (2) | IL286282B2 (https=) |
| MX (2) | MX394865B (https=) |
| MY (1) | MY193968A (https=) |
| NZ (1) | NZ734256A (https=) |
| RU (1) | RU2723021C2 (https=) |
| SG (1) | SG11201706281YA (https=) |
| WO (1) | WO2016130839A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2593027T3 (es) | 2009-03-30 | 2016-12-05 | Eisai R&D Management Co., Ltd. | Composición liposomal |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| MX383691B (es) | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| HK1249051A1 (zh) | 2015-03-06 | 2018-10-26 | BeyondSpring Pharmaceuticals Inc. | 治疗脑肿瘤的方法 |
| AU2016275574B2 (en) * | 2015-06-11 | 2019-07-11 | Bionomics Limited | Pharmaceutical combination and uses thereof |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| WO2017139231A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| US12029724B2 (en) | 2016-04-28 | 2024-07-09 | Eisai R&D Management Co., Ltd. | Method for inhibiting tumor growth |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| RU2760348C2 (ru) | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| EP3505183B1 (en) * | 2016-08-26 | 2022-03-30 | Tetsuji Okuno | Microvascular blood flow decreasing agent and use thereof |
| BR112019007145A2 (pt) * | 2016-10-14 | 2019-07-02 | Eisai R&D Man Co Ltd | combinação de um antagonista de pd-1 e eribulina para o tratamento de câncer urotelial |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| AU2018236168B2 (en) * | 2017-03-13 | 2024-02-29 | Beyondspring Pharmaceuticals, Inc. | Compositions of plinabulin and use thereof |
| CN110913856A (zh) * | 2017-07-26 | 2020-03-24 | 株式会社钟根堂 | 包含血管破坏剂及免疫检查点抑制剂的用于预防或治疗癌症的组合物 |
| AU2018328773B2 (en) * | 2017-09-08 | 2023-11-16 | University Health Network | Combination therapies for inhibition of Polo-like Kinase 4 |
| CN109498627B (zh) * | 2017-09-15 | 2021-06-04 | 深圳华大海洋科技有限公司 | 一种治疗肿瘤的药物组合物及其应用 |
| KR20200112881A (ko) * | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| ES3060133T3 (en) * | 2018-06-01 | 2026-03-25 | Beyondspring Pharmaceuticals Inc | Composition and method of treating cancer associated with egfr mutation |
| CN108524442B (zh) * | 2018-06-05 | 2022-01-28 | 深圳海王医药科技研究院有限公司 | 一种抗肿瘤药物的注射剂及其制备方法 |
| CA3109223A1 (en) * | 2018-08-16 | 2020-02-20 | Beyondspring Pharmaceuticals, Inc. | Method and composition for stimulating immune response |
| WO2020092887A2 (en) * | 2018-11-01 | 2020-05-07 | North Carolina State University | Adipocyte mediated delivery of anticancer therapeutics |
| CN110265095A (zh) * | 2019-05-22 | 2019-09-20 | 首都医科大学附属北京佑安医院 | 用于hcc复发及rfs的预测模型和诺模图的构建方法及应用 |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| CN112778155B (zh) * | 2019-11-11 | 2023-08-11 | 大连万春布林医药有限公司 | 妥卡雷琐衍生物及其用途 |
| KR20230006568A (ko) * | 2020-05-04 | 2023-01-10 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 낮은 면역원성을 갖는 암에서 암세포 사멸을 강화하기 위한 삼중 병용 요법 |
| WO2022133492A1 (en) * | 2020-12-18 | 2022-06-23 | Beyondspring Pharmaceuticals, Inc. | Compositions and methods for generating anti-tumor immune response |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| WO2024191805A1 (en) * | 2023-03-10 | 2024-09-19 | Beyondspring Pharmaceuticals, Inc. | Oncology combination therapy and methods of use |
| WO2025006507A1 (en) * | 2023-06-27 | 2025-01-02 | Beyondspring Pharmaceuticals, Inc. | Oncology combination therapy and methods of use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0313363A (pt) * | 2002-08-02 | 2005-08-09 | Nereus Pharmaceuticals Inc | Deidrofenilahistinas e seus análogos, e sua sìntese |
| EP1711487A1 (en) * | 2004-02-04 | 2006-10-18 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| RU2494107C2 (ru) * | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| US8569262B2 (en) * | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US8449886B2 (en) * | 2008-01-08 | 2013-05-28 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| WO2010045580A1 (en) * | 2008-10-17 | 2010-04-22 | Exelixis, Inc. | Sphingosine-1-phosphate receptor antagonists |
| US20110160159A1 (en) * | 2009-09-15 | 2011-06-30 | John Ryan | Treatment of cancer |
| EP2571577A1 (en) * | 2010-05-17 | 2013-03-27 | Bristol-Myers Squibb Company | Improved immunotherapeutic dosing regimens and combinations thereof |
| WO2012035436A1 (en) * | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
| US20150004175A1 (en) * | 2011-12-13 | 2015-01-01 | Yale University | Compositions and Methods for Reducing CTL Exhaustion |
| JP6457940B2 (ja) * | 2012-08-30 | 2019-01-23 | アムジエン・インコーポレーテツド | 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法 |
| CA2889182A1 (en) * | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| DK2958943T3 (da) * | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
| EP2958571B1 (en) * | 2013-02-21 | 2024-04-10 | Michele Maio | Dna hypomethylating agents for cancer therapy |
| US10260038B2 (en) * | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| SG11201509742QA (en) * | 2013-06-03 | 2015-12-30 | Novartis Ag | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
| JP6411523B2 (ja) * | 2013-10-11 | 2018-10-24 | ビヨンドスプリング インコーポレイテッド | プリナブリン及びタキサンの組合せがん治療 |
| WO2017139231A1 (en) * | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
-
2016
- 2016-02-11 AU AU2016219204A patent/AU2016219204B2/en active Active
- 2016-02-11 RU RU2017127966A patent/RU2723021C2/ru active
- 2016-02-11 CA CA2975729A patent/CA2975729A1/en active Pending
- 2016-02-11 HK HK18107194.9A patent/HK1247816A1/zh unknown
- 2016-02-11 SG SG11201706281YA patent/SG11201706281YA/en unknown
- 2016-02-11 MY MYPI2017702826A patent/MY193968A/en unknown
- 2016-02-11 KR KR1020177025140A patent/KR20170117113A/ko not_active Ceased
- 2016-02-11 MX MX2017010338A patent/MX394865B/es unknown
- 2016-02-11 CN CN201680015268.XA patent/CN107427510A/zh active Pending
- 2016-02-11 IL IL286282A patent/IL286282B2/en unknown
- 2016-02-11 NZ NZ734256A patent/NZ734256A/en unknown
- 2016-02-11 KR KR1020247022015A patent/KR20240110996A/ko active Pending
- 2016-02-11 JP JP2017560890A patent/JP7243021B2/ja active Active
- 2016-02-11 WO PCT/US2016/017602 patent/WO2016130839A1/en not_active Ceased
- 2016-02-11 CN CN202311274843.6A patent/CN117100753A/zh active Pending
- 2016-02-11 EP EP16749903.7A patent/EP3256130A4/en active Pending
- 2016-02-11 US US15/550,350 patent/US20180028531A1/en not_active Abandoned
-
2017
- 2017-08-01 IL IL253784A patent/IL253784B/en unknown
- 2017-08-10 MX MX2022007472A patent/MX2022007472A/es unknown
- 2017-08-10 CL CL2017002050A patent/CL2017002050A1/es unknown
-
2021
- 2021-01-07 JP JP2021001505A patent/JP7157181B2/ja active Active
- 2021-04-21 AU AU2021202416A patent/AU2021202416B2/en active Active
-
2022
- 2022-11-01 JP JP2022175377A patent/JP7564172B2/ja active Active
-
2024
- 2024-02-02 AU AU2024200672A patent/AU2024200672B2/en active Active
- 2024-09-26 JP JP2024167302A patent/JP2024174070A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508572A5 (https=) | ||
| RU2017127966A (ru) | Применение плинабулина в комбинации с ингибиторами контрольной точки иммунного ответа | |
| JP2019511565A5 (https=) | ||
| Constantinidou et al. | Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy | |
| IL266563B (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| JP2022088662A5 (https=) | ||
| IL292658A (en) | Immune modulation with tlr9 agonists for cancer treatment | |
| RU2020124007A (ru) | Комбинированный препарат, включающий агонист tlr7 | |
| JP2021524744A5 (https=) | ||
| UY37758A (es) | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos | |
| HRP20202042T1 (hr) | Modulacija tumorske imunosti | |
| FI3827838T3 (fi) | Sytokiini-indusoidun sh2-proteiinin estäminen nk-soluissa | |
| NZ750256A (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| RU2020127099A (ru) | Способ улучшения функции иммунных клеток и оценки мультифункциональности иммунных клеток | |
| JP2013166763A5 (https=) | ||
| RU2017107681A (ru) | Производные хиназолина | |
| Urba et al. | Immunomodulatory activity of nivolumab monotherapy in patients with advanced melanoma | |
| Mantaj et al. | Interaction of SJG-136 with cognate sequences of oncogenic transcription factors. | |
| Huang et al. | Development and characterization of a bispecific antibody (GB265) against PD-L1 and TIGIT | |
| Andrews et al. | Abstract A060: Inhibition of Aurora B kinase activity triggers senescence that can be bypassed by blocking p53 and RB function, promoting replication stress | |
| Abbineni et al. | Abstract A046: Identification of paralog selective degraders of SMARCA2 and SMARCA4 for treatment of various cancers | |
| Ring et al. | Abstract A191: FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy | |
| Yu et al. | In vivo combination of miransertib (ARQ 092) with anti-PD-1 antibody, trametinib, lapatinib, trastuzumab and paclitaxel | |
| Guo et al. | N1-hexyl-N5-benzyl-biguanide promotes proliferation of CD4+ and CD8+ T lymphocytes | |
| Zhang et al. | Discovery of novel TAM family kinase inhibitors |